We investigated the effects of first-line ET in combination with CDK 4/6i treatment on OS and PFS in HER2-low and zero groups in patients with metastatic HR + /HER2-negative BC and we found no significant difference between the two groups in both OS and PFS. Here, ERBB2 is linked to breast cancer.